Mineralys Therapeutics Inc.
MLYS | NASDAQ
$28.31
+$0.29 (+1.03%)
At close: Sep 21, 2026, 4:00 PM ET
$28.01
-$0.30 (-1.06%)
Pre-market:
Sep 22, 2026, 4:10 AM ET
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Key Executives
| Name | Position |
|---|---|
| Jon Congleton | President, Chief Executive Officer & Director |
| Adam Scott Levy | Chief Financial Officer & Secretary |
| Jeffrey A. Munsie | Chief Legal Officer |
| Brian Taylor Slingsby | Founder & Executive Director |
| Danielle Mahoney | Senior Vice President of Quality Assurance |
| David Rodman | Chief Medical Officer |
| Eric J. Warren | Chief Commercial Officer |
| James J. Ferguson FACC | Chief Medical Officer |
| Jessica Ibbitson | Executive Vice President of Operations |
| Jose Breton | Senior Vice President of Finance & Controller |
| Michael Tortorici | Senior Vice President of Translational Medicine |
| Robert McKean | Senior Vice President of CMC |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2026 | 4 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 12, 2026 | 3 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 23, 2026 | 4 | Filing |
| Jul 20, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
Mineralys Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 9, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Jon Congleton |
Contact Details
150 N. Radnor Chester Rd. Radnor,
Pennsylvania 19087 United States
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| SIC Code | 2834 |
Recent News
- 2 days ago / defenseworld.netInsider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock
- 19 days ago / seekingalpha.comMineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
- 27 days ago / globenewswire.comMineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
- 1 month ago / seekingalpha.comMineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
- 1 month ago / marketbeat.comMineralys Therapeutics Q2 Earnings Call Highlights
- 1 month ago / globenewswire.comMineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- 3 months ago / fool.comWhat a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
- 3 months ago / seekingalpha.comMineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- 4 months ago / globenewswire.comMineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- 4 months ago / globenewswire.comMineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Add to Watchlist
Select watchlists to add or remove MLYS